Statements (55)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:bfsLayer |
4
|
| gptkbp:bfsParent |
gptkb:Endometriosis
|
| gptkbp:activities |
suppressing gonadotropin release
|
| gptkbp:affects |
bone density loss
metabolic changes testosterone levels pituitary gland cardiovascular risks estrogen levels |
| gptkbp:appointed_by |
gptkb:fragrance
injection |
| gptkbp:clinical_trial |
Phase II
Phase III Phase I |
| gptkbp:contraindication |
pregnancy
breastfeeding hypersensitivity to the drug |
| gptkbp:developed_by |
gptkb:1980s
|
| gptkbp:example |
gptkb:goserelin
gptkb:leuprolide gptkb:triptorelin nafarelin |
| gptkbp:formulation |
gptkb:fragrance
injectable solution implant |
| https://www.w3.org/2000/01/rdf-schema#label |
Gn RH agonists
|
| gptkbp:interacts_with |
anticoagulants
hormonal contraceptives other hormone therapies |
| gptkbp:invention |
patented
generic available |
| gptkbp:is_used_for |
treating endometriosis
treating precocious puberty treating hormone-sensitive cancers |
| gptkbp:manager |
subcutaneous
intranasal intramuscular |
| gptkbp:marketed_as |
gptkb:Lupron
gptkb:Zoladex gptkb:Trelstar Synarel |
| gptkbp:population |
adult men
adult women children with precocious puberty |
| gptkbp:regulatory_compliance |
FDA approved
EMA approved |
| gptkbp:research_focus |
gptkb:healthcare_organization
reproductive health fertility preservation endometriosis management |
| gptkbp:side_effect |
osteoporosis
mood changes hot flashes decreased libido |